Weight MaintenanceAFTER-GLPNCT07701460
Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1
A study testing Digital Behavioral Application in people with Weight Maintenance, run by Tufts University at 1 site in United States.
Trial summary
Many people who use GLP-1 medications (such as semaglutide or tirzepatide) achieve meaningful weight loss, but maintaining that weight loss off after stopping the medication can be very challenging. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Weight Maintenance
- What is being tested?
- Digital Behavioral Application
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Oct 2026to 31 Jul 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years of age or older (no upper limit);
- ability to read, write, and speak English and/or Spanish;
- ability to provide informed consent;
- less than 30-days since GLP-1 RA cessation;
- willing to participate.
Who cannot join
- No clinically significant weight loss (e.g., < 5% body weight) while taking GLP medication;
- major psychiatric illness, cognitive impairment, or substance misuse that could impair ability to participate;
- medical conditions that significantly affect weight or make participation unsafe (e.g., pregnancy or breastfeeding, recent bariatric surgery, current use of GLP 1 or other anti-obesity medications, or endocrine disorders that alter weight regulation);
- inability to use a smartphone or complete remote study procedures;
- participation in another weight loss or maintenance program or clinical trial judged by investigators to interfere with study involvement;
- Adults unable to consent (cognitively impaired);
- Wards of the state;
- Anyone under age 18.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
This study is conducted remotely
Boston, Massachusetts, 02111
About this study
Many people who use GLP-1 medications (such as semaglutide or tirzepatide) achieve meaningful weight loss, but maintaining that weight loss off after stopping the medication can be very challenging. Researchers at Tufts University are conducting a study to learn whether a digital lifestyle program can help people maintain their weight loss after they stop taking a GLP-1 medication.
Adults who have recently stopped a GLP-1 medication may be eligible to participate. Participants will be randomly assigned to either receive access to a digital program or to continue with usual care. The study lasts 12 months and is fully remote. All participants will receive a Bluetooth scale to track weight from home and will complete short online questionnaires several times over the year.
By taking part, participants can help researchers better understand how to support long-term weight maintenance in a way that is affordable, accessible, and sustainable. Participants are compensated for their time, and involvement may help improve care for others with similar experiences.
- Conditions
- Weight Maintenance
- Being tested
- Digital Behavioral Application
- Keywords
- Obesity, Overweight, Glucagon-Like Peptide-1 Receptor Agonists, Digital Health, Lifestyle Intervention, Mobile Applications, Weight Maintenance, Eating Behavior
- Medical subject headings
- Obesity, Overweight, Feeding Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital Behavioral ApplicationBehavioural
Noom® provides well-established behavioral strategies for weight loss and weight maintenance, such as self-monitoring of diet, exercise, and weight. What Noom® adds is education on the physiological, psychological, social, and environmental factors that influence eating behavior and tools that increase self-efficacy for dealing with those stimuli. For example, Noom® has a lesson that defines social triggers, explains the influence social triggers have on motivation to eat, and asks the participant to identify their own social triggers and a plan for managing triggers should they come up. Then the app prompts participants to report back on how they managed or struggled to manage a trigger and responds accordingly. Participants will be prescribed 15 minutes of use per day per Noom® recommendations, which includes interactive lessons, food logging, and weigh-ins.
| Study group | Role | What they receive |
|---|---|---|
| Noom® Smart device Application Subscription | Experimental | Not described Receives: Behavioral: Digital Behavioral Application |
| Usual care | No intervention | Usual care for weight loss maintenance includes ongoing nutrition, exercise, and lifestyle counseling. However, the implementation of this standard of care is highly variable and dependent on the provider's discretion and availability. In many cases it is nothing. In some cases, the patient may have 1-2 office or remote visits with a provider or dietitian who educates the patient on nutrition and exercise behaviors. "Usual care" is left to each providers' discretion and will identify how much counseling (if any) participants receive through self-report. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of weight loss maintained
Percentage of weight loss maintained over 12 months following GLP-1 medication cessation measured using study-provided Bluetooth scale.
Measured: 12-months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start15 Oct 2026 (estimated)
- Primary completion31 Jan 2028 (estimated)
- Study completion31 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Weight MaintenanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- This is a 2-arm parallel group open-label randomized controlled trial (RCT) with randomization stratified on 3 factors: (1) prior use of digital behavioral support (Y/N); (2) amount of weight loss (kg) while on GLP-1 (5-10% body weight vs. \>10% body weight); and (3) weight status (with vs without obesity, obesity defined as BMI ≥ 25).
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tufts University
- Sponsor type
- University, hospital or other
- Collaborators
- Noom Inc.
- Responsible party
- Sponsor
- Investigators
- Kelseanna Hollis-Hansen, PhD, MPH, Principal investigator, Tufts University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07701460
- Sponsor's protocol ID
- STUDY00007074
- Acronym
- AFTER-GLP
- Status last verified
- Jul 2026
- First submitted
- 8 Jul 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Sharing of IPD will be at the discretion of the funder.